Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter shows Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedA new revision label 'v3.3.2' appears, replacing 'v3.2.0', indicating a site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the generic government funding and operating status notice from the page; study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedNo changes detected; the two screenshots show the same study details page.SummaryDifference0.4%

- Check91 days agoChange Detected- Added a government funding notice with operational details and links; - Updated version to v3.2.0; - Removed reference to v3.1.0.SummaryDifference3%

- Check98 days agoChange DetectedUpdate indicates a new software release (v3.1.0) replacing the previous v3.0.2—no other substantive content changes are shown.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.